|
||||
|
|
|
|
|
|
ABOUT AMI RESEARCH AMI Research provides credible advocacy to deserving microcap companies by combining institutional-level research and customized graphics into detailed analyst reports. Unlike many issuer-paid research firms, AMI abides by CFA Institute and NIRI standards, ensuring coverage is objective and transparent. Through a comprehensive initial report and three subsequent quarterly updates, AMI Research provides a high visibility review of a company’s business model, industry, intrinsic value and prospects. Coverage includes a detailed valuation model, a recommendation and a target share price range based on fundamental, bottom-up analysis. Conclusions are supported by well-documented analysis that differentiates fact from opinion and explains critical details that investors need to know about a company. An AMI Research report is an invaluable source of investment ideas, available free to self-directed investors. Coverage by AMI ensures an objective explanation of all facets of a business and increased exposure to numerous prospective investors seeking reputable investment ideas. Wide Distribution The quality of AMI Research reports, combined with a proprietary opt-in e-mail alert list and free subscription model, has resulted in a wide and prestigious audience. Reports are available through Thomson/First Call, Investars and the company’s own AMIStockreports.com site. AMI RESEARCH is a division of Hawk Associates. Hawk Associates helps small and microcap companies build valuation, support and credibility on Wall Street through long-term strategies that leverage unique talents and investment industry relationships developed since 1995. AMI Research provides issuer-paid research in accordance with the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationship developed by the CFA Institute and National Investor Relations Institute, and as per the disclosures included in each research report. Our disclaimer can be found here.
|
|
AMI MANAGEMENT
Brian E. Wong, Brian previously conducted sell-side equity research with Broadpoint Capital and First Albany Capital, where he was a member of the Wall Street Journal’s Top Five Equity Analyst Team in 2002 and 2003. With a background in the medical technology and healthcare sector, Brian provided in-depth investment research reports on companies in the orthopedic, neurotechnology, diabetes, plastics and general surgery sectors. Brian’s early career began at the University of Pennsylvania Medical School and later at the West Roxbury VA Medical Center and Brigham and Women’s' Hospital, Orthopedic Research Laboratory as a biomechanical engineer where he conducted research in biomechanics and orthopedics. After earning his B.S. from the University of Pennsylvania, Brian furthered his Post Baccalaureate studies at Harvard and obtained his Master’s of Science and Master’s of Engineering Management from Dartmouth College.
|
|
||||
